The Role of Janus Kinases in the Treatment of Autoimmune Skin Diseases

The JAK/STAT signaling pathway was identified as crucial in the pathomechanisms of autoimmune skin diseases such as vitiligo, psoriasis, alopecia areata, and atopic dermatitis, where it mediates lymphocyte differentiation and cytokine-induced inflammation. The inhibition of this pathway emerged as a promising target for treatment, leading to the development of Janus kinase inhibitors (jakinibs). These inhibitors, which could be administered orally or topically, showed effectiveness in treating various hematological and inflammatory diseases, including the aforementioned skin conditions. The article highlighted the potential of selective JAK inhibitors as a new therapeutic horizon, emphasizing their utility in managing inflammatory dermatoses.